Draft:Mindset Health
Submission declined on 18 June 2026 by CopyleftEverything (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice.
Declined by IAmChaos 10 months ago.Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use. | |
Comment: Long paragraph begins: "Nerva has been the subject of real-world studies" and lists studies conducted, but not their results or whether the studies were independently conducted. Come on, man. CopyleftEverything (talk) 02:43, 18 June 2026 (UTC)
| Type | Private |
|---|---|
| Industry | Digital therapeutics |
| Founded | 2018 |
| Founders | Alex Naoumidis, Chris Naoumidis |
| Headquarters | , Australia |
| Products | Nerva, Evia, Finito |
Mindset Health Pty Ltd is an Australian digital therapeutics company based in Melbourne that develops mobile applications delivering hypnotherapy-based programs for chronic health conditions.[1] It was founded by brothers Alex and Chris Naoumidis. Its main product, Nerva, delivers gut-directed hypnotherapy for irritable bowel syndrome.[2]
History
[edit]Mindset Health was founded by brothers Alex and Chris Naoumidis in 2018[1] and took part in the Y Combinator startup accelerator.[3] Its first product, Nerva, launched in June 2019.[1] The company raised about A$6.7 million in 2021[4] and a further A$17.8 million (US$12 million) in 2023 led by King River Capital, at a reported valuation of about A$77 million,[1] bringing its total funding to about A$24.5 million.[5] In May 2025 it acquired the assets of the U.S. digital therapeutics company Mahana Therapeutics.[6]
Products
[edit]Mindset Health's products include Nerva, for irritable bowel syndrome;[2] Evia, for menopausal hot flashes;[7] and Finito, for smoking cessation.[1]
Research
[edit]Nerva has been the subject of real-world studies presented at Digestive Disease Week (DDW). Researchers at Monash University reported on adherence and symptom outcomes in a cohort of about 195,000 users[8] and on outcomes in IBS patients with co-morbid inflammatory bowel disease.[9] Collaborators at Mount Sinai studied outcomes in patients with concurrent upper gastrointestinal symptoms,[10] and researchers at Mayo Clinic examined gender differences in early program attrition[11] and the addition of diaphragmatic breathing to gut-directed hypnotherapy.[12] An independent 2024 review in Clinical Gastroenterology and Hepatology identified Nerva as one of the few digital therapeutics for IBS with published clinical evidence.[13]
References
[edit]- 1 2 3 4 5 Tess Bennett (2023-03-21). "Melbourne brothers build a $77m business from hypnotherapy apps". Australian Financial Review.
- 1 2 Anderson EJ, Peters SL, Gibson PR, Halmos EP (February 2025). "Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome". American Journal of Gastroenterology. 120 (2): 440–448. doi:10.14309/ajg.0000000000002921. PMID 38940439.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ↑ "Hypnosis for health? Investors have placed a $1.1 million bet on Mindset Health that it can work". TechCrunch. 2020-05-15.
- ↑ "Evidence-based hypnotherapy app raises $6.7m". Australian Financial Review. 2021-06-25.
- ↑ "Student startup Mindset Health raises $20 million". Monash University. 2023-03-22.
- ↑ "Nerva Completes Mahana Therapeutics Acquisition to Expand Access to Digital Therapies for IBS" (Press release). Mindset Health. 2025-05-06 – via BioSpace.
- ↑ Snyder M, Elkins GR (2024-03-14). "Characteristics of Users of a Digital Hypnotherapy Intervention for Hot Flashes: Retrospective Study". JMIR Formative Research. 8 e53555. doi:10.2196/53555. PMC 10979336. PMID 38483465.
- ↑ Peters SL, Gibson PR, Halmos EP (2026). "Longitudinal improvement in adherence and efficacy of app-delivered gut-directed hypnotherapy". Gastroenterology. doi:10.1016/S0016-5085(26)04445-8.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ↑ Peters SL, Gibson PR, Halmos EP (2026). "Efficacy of app-delivered gut-directed hypnotherapy in irritable bowel syndrome patients with co-morbid IBD". Gastroenterology. doi:10.1016/S0016-5085(26)04437-9.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ↑ Noorani S, Brand D, Naoumidis C, Hall C, Smith MS, Jodorkovsky D, Luo Y (2026). "Brain-gut behavioral therapy program for IBS benefits patients with concurrent upper GI symptoms". Gastroenterology. doi:10.1016/S0016-5085(26)04658-5.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ↑ Hoeg A, Jin M, Wang I (2026). "Gender differences in early attrition during digitally delivered brain-gut behavioral therapy for IBS". Gastroenterology. doi:10.1016/S0016-5085(26)04738-4.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ↑ Jin M, Wang I (2026). "Enhanced irritable bowel syndrome symptom improvement with diaphragmatic breathing when added to gut-directed hypnotherapy". Gastroenterology.
- ↑ Brenner DM, Ladewski AM, Kinsinger SW (2024). "Development and Current State of Digital Therapeutics for Irritable Bowel Syndrome". Clinical Gastroenterology and Hepatology. 22 (2): 222–234. doi:10.1016/j.cgh.2023.09.012. PMID 37743035.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
- Reliable sources include: reputable newspapers, magazines, academic journals, and books from respected publishers.
- Unacceptable sources include: personal blogs, social media, predatory publishers, most tabloids, and websites where anyone can contribute.
Replace any unreliable sources with high-quality sources. If you cannot find a reliable source for the material, it should be removed.